Skip to main content
Premium Trial:

Request an Annual Quote

Spotfire, Rosetta Integrate Platforms

NEW YORK, May 28 - Spotfire and Rosetta Biosoftware said today they will integrate their DecisionSite and Resolver technologies.


Under the three-year deal, current and future customers who subscribe to the platforms will be able to use both products simultaneously.

The integration will be available as early as July at no additional cost to customers who use both tools. It will take place either over the Internet or through an installation process, said David Butler, vice president of product strategy and marketing at Spotfire.


Click here for more information.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.